Madhavan Nallani

Company: ACM Biosciences

Job title: CEO

Bio:

Dr Nallani founded ACM Biolabs in 2013, based his polymeric nanoparticle research work in Germany, the Netherlands and Singapore. He holds a PhD from Jacobs University in Germany and before starting ACM was an Assistant Professor at Nanyang Technological University, Singapore. He has lead ACM from its inception through to its current status as a clinical stage biotech with multiple diverse assets and presence in Singapore, Switzerland and Australia.

Seminars:

Thermostable mRNA Vaccines using Hybrid Polymer-Lipid Nanoparticles 12:00 pm

Presenting a polymer-based nanoparticles for vaccines and therapeutics Highlighting 12-month stability data of liquid formulations at 2 – 80°C and improvements related to anti-PEG antibodies and response durability Outlining a CEPI funded rabies mRNA vaccine programRead more

day: Day Two